Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Silence Therapeutics Plc ADR (SLN)

Silence Therapeutics Plc ADR (SLN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 688,344
  • Shares Outstanding, K 29,928
  • Annual Sales, $ 31,560 K
  • Annual Income, $ -53,820 K
  • 60-Month Beta 1.38
  • Price/Sales 21.76
  • Price/Cash Flow N/A
  • Price/Book 32.37
Trade SLN with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.17
  • Number of Estimates 2
  • High Estimate -0.11
  • Low Estimate -0.23
  • Prior Year -0.36
  • Growth Rate Est. (year over year) +52.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.65 +11.38%
on 05/14/24
23.86 -3.60%
on 05/09/24
+1.44 (+6.68%)
since 04/17/24
3-Month
19.48 +18.07%
on 04/09/24
27.72 -17.03%
on 03/14/24
+0.83 (+3.74%)
since 02/16/24
52-Week
4.84 +375.21%
on 07/25/23
27.72 -17.03%
on 03/14/24
+17.55 (+322.02%)
since 05/17/23

Most Recent Stories

More News
New Strong Sell Stocks for May 9th

ARCB, MRVL and SLN have been added to the Zacks Rank #5 (Strong Sell) List on May 9, 2023.

MRVL : 71.92 (-1.59%)
ARCB : 113.78 (-1.21%)
SLN : 23.00 (+0.26%)
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through...

SLN : 23.00 (+0.26%)
Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through...

SLN : 23.00 (+0.26%)
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through...

SLN : 23.00 (+0.26%)
Silence Therapeutics Announces Publication in Blood Demonstrating Role for Iron Regulation in Polycythemia Vera

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through...

SLN : 23.00 (+0.26%)
Silence Therapeutics to Present at Guggenheim’s Genomic Medicines and Rare Disease Days

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through...

SLN : 23.00 (+0.26%)
Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through...

SLN : 23.00 (+0.26%)
Silence Therapeutics to Buyback siRNA Complement Assets

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through...

SLN : 23.00 (+0.26%)
Silence Therapeutics Reports Fourth Quarter and Full Year 2022 Results

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through...

SLN : 23.00 (+0.26%)
Silence Therapeutics PLC Sponsored ADR (SLN) Stock Jumps 9.3%: Will It Continue to Soar?

Silence Therapeutics PLC Sponsored ADR (SLN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving...

SLN : 23.00 (+0.26%)
OPTN : 1.2600 (-2.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Silence Therapeutics plc focuses on the discovery, development and delivery of novel RNA therapeutics in hematology, cardiovascular and other rare and metabolic indications. The Company's product candidate consist SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease...

See More

Key Turning Points

3rd Resistance Point 24.65
2nd Resistance Point 24.22
1st Resistance Point 23.61
Last Price 23.00
1st Support Level 22.57
2nd Support Level 22.14
3rd Support Level 21.53

See More

52-Week High 27.72
Last Price 23.00
Fibonacci 61.8% 18.98
Fibonacci 50% 16.28
Fibonacci 38.2% 13.58
52-Week Low 4.84

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar